Acumen Pharmaceuticals

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.

Acumen Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Therapeutics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $24.8B in funding across 84 round(s). With a team of 11-50 employees, Acumen Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Acumen Pharmaceuticals, raised $1.5M. Discover more about their projects, partnerships, and impact on our platform.